PE20221465A1 - ANTI-TREM2 ANTIBODIES AND METHODS OF USING THEM - Google Patents

ANTI-TREM2 ANTIBODIES AND METHODS OF USING THEM

Info

Publication number
PE20221465A1
PE20221465A1 PE2022001437A PE2022001437A PE20221465A1 PE 20221465 A1 PE20221465 A1 PE 20221465A1 PE 2022001437 A PE2022001437 A PE 2022001437A PE 2022001437 A PE2022001437 A PE 2022001437A PE 20221465 A1 PE20221465 A1 PE 20221465A1
Authority
PE
Peru
Prior art keywords
trem2
methods
antibody
polypeptide
trem2 antibodies
Prior art date
Application number
PE2022001437A
Other languages
Spanish (es)
Inventor
Mark S Dennis
Zhenyu Gu
Mihalis S Kariolis
Cathal S Mahon
Kathryn M Monroe
Joshua I Park
Rachel Prorok
Adam P Silverman
Lengerich Bettina Van
Original Assignee
Denali Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Denali Therapeutics Inc filed Critical Denali Therapeutics Inc
Priority claimed from PCT/US2021/013200 external-priority patent/WO2021146256A1/en
Publication of PE20221465A1 publication Critical patent/PE20221465A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Abstract

La presente invencion proporciona un anticuerpo que se unen especificamente a un receptor activador humano expresado en las celulas mieloides 2 (TREM2) caracterizado porque comprende (a) una region variable que comprende las secuencias de las regiones determinantes de complementariedad (CDRs): H1, H2, H3, L1, L2 y L3; (b) un primer polipeptido Fc modificado para unirse especificamente a un receptor de transferrina; y (c) un segundo polipeptido Fc. Tambien refiere a una composicion farmaceutica que lo comprende Dicho anticuerpo potencia la actividad del TREM2 o disminuye los niveles de TREM2 soluble (sTREM2); siendo util para tratar una enfermedad neurodegenerativaThe present invention provides an antibody that specifically binds to a human activating receptor expressed in myeloid cells 2 (TREM2) characterized in that it comprises (a) a variable region comprising the sequences of the complementarity determining regions (CDRs): H1, H2 , H3, L1, L2 and L3; (b) a first Fc polypeptide modified to specifically bind to a transferrin receptor; and (c) a second Fc polypeptide. It also refers to a pharmaceutical composition comprising said antibody enhances the activity of TREM2 or decreases the levels of soluble TREM2 (sTREM2); being useful to treat a neurodegenerative disease

PE2022001437A 2020-01-13 2021-01-13 ANTI-TREM2 ANTIBODIES AND METHODS OF USING THEM PE20221465A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202062960663P 2020-01-13 2020-01-13
US202063070728P 2020-08-26 2020-08-26
US202063091717P 2020-10-14 2020-10-14
PCT/US2021/013200 WO2021146256A1 (en) 2020-01-13 2021-01-13 Anti-trem2 antibodies and methods of use thereof

Publications (1)

Publication Number Publication Date
PE20221465A1 true PE20221465A1 (en) 2022-09-21

Family

ID=76760857

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2022001437A PE20221465A1 (en) 2020-01-13 2021-01-13 ANTI-TREM2 ANTIBODIES AND METHODS OF USING THEM

Country Status (12)

Country Link
US (2) US11124567B2 (en)
EP (1) EP4090682A1 (en)
JP (1) JP2023512450A (en)
KR (1) KR20220131246A (en)
CN (1) CN115279790A (en)
AU (1) AU2021208482A1 (en)
BR (1) BR112022013756A2 (en)
CA (1) CA3166385A1 (en)
CO (1) CO2022009744A2 (en)
IL (1) IL294655A (en)
MX (1) MX2022008582A (en)
PE (1) PE20221465A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018221731C1 (en) 2017-02-17 2021-11-18 Denali Therapeutics Inc. Engineered transferrin receptor binding polypeptides
MX2020002918A (en) 2017-10-02 2020-07-22 Denali Therapeutics Inc Fusion proteins comprising enzyme replacement therapy enzymes.
CN114981297A (en) 2019-12-23 2022-08-30 戴纳立制药公司 Proteinogenin variants
IL302029A (en) 2020-10-14 2023-06-01 Denali Therapeutics Inc Fusion proteins comprising sulfoglucosamine sulfohydrolase enzymes and methods thereof
WO2023192288A1 (en) * 2022-03-28 2023-10-05 Denali Therapeutics Inc. Monovalent anti-trem2 binding molecules and methods of use thereof
WO2024040195A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
CN117624360A (en) * 2022-08-26 2024-03-01 南京融捷康生物科技有限公司 Single-domain antibody for resisting TREM2 and application thereof
WO2024052343A1 (en) 2022-09-06 2024-03-14 Institut National de la Santé et de la Recherche Médicale Trem-2 agonists for the treatment of marfan syndrome
CN116041481B (en) * 2022-09-13 2024-01-19 北京湃德智健科技有限公司 Antigen polypeptide for detecting TREM2 autoantibody and application thereof

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8981061B2 (en) 2001-03-20 2015-03-17 Novo Nordisk A/S Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof
US8231878B2 (en) 2001-03-20 2012-07-31 Cosmo Research & Development S.P.A. Receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
EP2810652A3 (en) 2009-03-05 2015-03-11 AbbVie Inc. IL-17 binding proteins
EP2992013B1 (en) 2013-04-29 2019-12-04 Teva Pharmaceuticals Australia Pty Ltd Anti-cd38 antibodies and fusions to attenuated interferon alpha-2b
EP3041865A2 (en) 2013-09-03 2016-07-13 NovImmune S.A. Readily isolated bispecific binding molecules with native format having mutated constant regions
CN105218669A (en) 2014-06-10 2016-01-06 河北翰林生物科技有限公司 Prepare the method for the human monoclonal antibodies of anti-human R47H-TREM2 mutant
JP6669749B2 (en) 2014-08-08 2020-03-18 アレクトル エルエルシー Anti-TREM2 antibody and method of using the same
CN106999585A (en) 2014-09-28 2017-08-01 加利福尼亚大学董事会 Regulation to excitant and non-irritating bone marrow cell
WO2017058866A1 (en) 2015-09-28 2017-04-06 Precision Immune, Inc. Anti-trem2 antibodies and uses thereof
CN117069841A (en) 2015-10-06 2023-11-17 艾利妥 anti-TREM 2 antibodies and methods of use thereof
WO2017147509A1 (en) 2016-02-25 2017-08-31 Marco Colonna Compositions comprising trem2 and methods of use thereof
EP3448874A4 (en) 2016-04-29 2020-04-22 Voyager Therapeutics, Inc. Compositions for the treatment of disease
WO2018015573A2 (en) 2016-07-22 2018-01-25 Deutsches Zentrum Für Neurodegenerative Erkrankungen E.V. (Dzne) Trem2 cleavage modulators and uses thereof
WO2018119351A1 (en) 2016-12-23 2018-06-28 Bluefin Biomedicine, Inc. Anti-sez6l2 antibodies and antibody drug conjugates
EP3570883A2 (en) 2017-01-17 2019-11-27 Yeda Research and Development Co. Ltd Methods of treating neurodegenerative diseases by inducing disease-associated microglia (dam) cells
US10457717B2 (en) * 2017-02-17 2019-10-29 Denali Therapeutics Inc. Engineered polypeptides
EP3583123A1 (en) * 2017-02-17 2019-12-25 Denali Therapeutics Inc. Anti-tau antibodies and methods of use thereof
AU2018221731C1 (en) * 2017-02-17 2021-11-18 Denali Therapeutics Inc. Engineered transferrin receptor binding polypeptides
JOP20190248A1 (en) 2017-04-21 2019-10-20 Amgen Inc Trem2 antigen binding proteins and uses thereof
KR20200032722A (en) 2017-07-27 2020-03-26 노파르티스 아게 Partial cleavage resistance TREM2 variant
ES2952982T3 (en) 2017-08-03 2023-11-07 Alector Llc Anti-TREM2 antibodies and methods of their use
CN111148757A (en) * 2017-08-10 2020-05-12 戴纳立制药公司 Engineered transferrin receptor binding polypeptides
CA3075285A1 (en) * 2017-09-14 2019-03-21 Denali Therapeutics Inc. Anti-trem2 antibodies and methods of use thereof
MX2020002918A (en) 2017-10-02 2020-07-22 Denali Therapeutics Inc Fusion proteins comprising enzyme replacement therapy enzymes.
US20210186917A1 (en) 2017-10-17 2021-06-24 The Translational Genomics Research Institute Trem2 agonists for the stimulation of microglia and methods of identification
WO2019094608A1 (en) * 2017-11-08 2019-05-16 Denali Therapeutics Inc. Anti-bace1 antibodies and methods of use thereof
EP3723803A4 (en) 2017-12-12 2021-09-15 Pionyr Immunotherapeutics, Inc. Anti-trem2 antibodies and related methods
JP2021510162A (en) 2018-01-10 2021-04-15 デナリ セラピューティクス インコーポレイテッドＤｅｎａｌｉ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． Transferrin receptor-binding polypeptide and its use
MX2020012518A (en) 2018-06-18 2021-02-16 Denali Therapeutics Inc Fusion proteins comprising progranulin.
GB201811404D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Anti-CD137 Antibodies
MX2021001711A (en) 2018-08-16 2021-05-27 Denali Therapeutics Inc Engineered bispecific proteins.
AU2019326545A1 (en) 2018-08-22 2021-03-11 Denali Therapeutics Inc. Anti-HER2 polypeptides and methods of use thereof
MX2021002616A (en) 2018-09-11 2021-05-12 Washington University St Louis Anti-trem-2 agonist antibodies.
UY38407A (en) 2018-10-15 2020-05-29 Novartis Ag TREM2 STABILIZING ANTIBODIES
KR102156165B1 (en) 2018-10-29 2020-09-15 재단법인대구경북과학기술원 Monoclonal antibody with specificity for human TREM2 protein, hybridoma cell line producing the same and use thereof
EP3887401A2 (en) 2018-11-26 2021-10-06 Denali Therapeutics Inc. Methods for treating dysregulated lipid metabolism
CA3122725A1 (en) 2018-12-10 2020-06-18 Mor Research Applications Trem2 antibodies and uses thereof
CA3121927A1 (en) 2018-12-10 2020-06-18 Denali Therapeutics Inc. Lysosomal storage disorder biomarkers and methods of use thereof
CN113194994A (en) 2018-12-11 2021-07-30 开拓免疫医疗公司 Methods of using anti-TREM 2 antibodies
EA202192294A1 (en) 2019-02-20 2021-12-24 Денали Терапьютикс Инк. ANTIBODIES TO TREM2 AND METHODS FOR THEIR APPLICATION
WO2020194317A1 (en) 2019-03-28 2020-10-01 Yeda Research And Development Co. Ltd. Method of treating lipid-related disorders
CA3134538A1 (en) 2019-04-03 2020-10-08 Denali Therapeutics Inc. Formulations of protein molecules comprising iduronate 2-sulfatase

Also Published As

Publication number Publication date
KR20220131246A (en) 2022-09-27
US20210214438A1 (en) 2021-07-15
CN115279790A (en) 2022-11-01
JP2023512450A (en) 2023-03-27
US20220177576A1 (en) 2022-06-09
AU2021208482A1 (en) 2022-07-21
US11124567B2 (en) 2021-09-21
CA3166385A1 (en) 2021-07-22
CO2022009744A2 (en) 2022-07-19
BR112022013756A2 (en) 2022-10-11
EP4090682A1 (en) 2022-11-23
MX2022008582A (en) 2022-08-10
IL294655A (en) 2022-09-01

Similar Documents

Publication Publication Date Title
PE20221465A1 (en) ANTI-TREM2 ANTIBODIES AND METHODS OF USING THEM
PE20231067A1 (en) ANTIBODIES AND FUSION PROTEINS THAT BIND CCR8 AND THEIR USES
PE20211284A1 (en) ANTI-NKG2A ANTIBODIES AND USES OF THEM
PE20211767A1 (en) ANTI-HLA-G ANTIBODIES, COMPOSITIONS INCLUDING ANTI-HLA-G ANTIBODIES AND METHODS OF USE OF ANTI-HLA-G ANTIBODIES
EA201691225A1 (en) ANTIBODY TO PD-1, ITS ANTIGEN-BINDING FRAGMENT AND THEIR MEDICAL APPLICATION
PE20140448A1 (en) BISPECIFIC BINDING MOLECULES BINDING VEGF AND ANG2
PE20090329A1 (en) HUMANIZED ANTIBODIES AGAINST GLOBULOMER AB (20-42) AND ITS USES
CO6251370A2 (en) A HUMANIZED CD20 UNION MOLECULA THAT INCLUDES AN IMMUNOGLOBULIN HEAVY CHAIN VARIABLE DOMAIN (VH) AND A LIGHT IMMUNOGLOBULINE CHAIN VARIABLE DOMAIN (VL) AND SAME USE METHODS
ECSP21010450A (en) ANTI-SORTILINA ANTIBODIES AND METHODS FOR THEIR USE
RU2014113046A (en) PREVENTION AND TREATMENT OF PATHOLOGICAL CONDITIONS OF EYES CAUSED BY KOMPLEMENT
RU2016100892A (en) ANTIBODIES AGAINST TWEAKR AND THEIR APPLICATION
AR079458A2 (en) CHEMICAL MONOCLONAL ANTIBODY THAT JOINS CD45
PE20230444A1 (en) ANTIBODIES
CO6260104A2 (en) ANTIBODIES AGAINST IL-25
EA202092420A1 (en) ANTIBODY AGAINST PD-L1 AND ITS APPLICATION
BR112018002436A2 (en) combination treatment of methods uses of these
PE20230839A1 (en) LAIR-1 BINDING AGENTS AND METHODS FOR THEIR USE
PE20221449A1 (en) CD8 BINDING AGENTS AND USES THEREOF
EA202190183A1 (en) ANTIBODIES TO SIGLEC-5 AND METHODS OF THEIR APPLICATION
PE20231187A1 (en) ANTI-PAR-2 ANTIBODIES AND METHODS OF USE THEREOF
JP2018531625A5 (en)
MX2020006155A (en) Bispecific cd 16-binding molecules and their use in the treatment of disease.
MX2022005949A (en) Anti-ror-2 antibodies and methods of use.
RU2020128081A (en) ANTIBODY AGAINST CD25 FOR TUMOR-SPECIFIC CELL DEPLETION
RU2011128702A (en) BUBBLE TREATMENT CONTAINING ANTIBODIES AGAINST FAS LIGAND